Company news
Sichuan Biokin Pharmaceutical Co., Ltd. Class A (SSE:688506) news
Sichuan Biokin Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: (688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement…
Press releases & updates
(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Temporary Use of Certain Idle Raised Funds to Supplement Working Capital
September 29, 2026
(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Appointment of Securities Affairs Representative
September 29, 2026
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase III Clinical Trial of T-Bren for Injection (HER2 ADC) for the Treatment of HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
September 29, 2026
(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Inclusion of T-Bren (HER2 ADC) in the List of Breakthrough Therapy Designations for Patients with HER2-Expressing Locally Advanced or Metastatic Biliary Tract Cancer Who Have Failed Platinum-based Chemotherapy
September 27, 2026
(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Inclusion of iza-bren (izalontamab brengitecan, BL-B01D1) in the List of Breakthrough Therapy Designations for Patients with Recurrent or Metastatic Biliary Tract Cancer Who Have Failed Prior Platinum-based Chemotherapy
September 27, 2026
(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for BL-M12D1 for Injection (ADC) for the Treatment of Hematological Malignancies
September 27, 2026
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Inclusion of BL-M05D1 for Injection in the List of Breakthrough Therapy Designations for Patients with CLDN18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Who Have Previously Received First-line Standard Treatment
September 27, 2026
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Early Return of Raised Funds Used to Temporarily Supplement Working Capital
September 23, 2026
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Triggering of Milestone Payment Conditions under the Global Strategic Collaboration Agreement between Its Wholly-owned Subsidiary SystImmune and Bristol Myers Squibb for Yizekang (Izalontamab Brengitecan, BL-B01D1/iza-bren)
September 21, 2026
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Joint Investment with Related Parties
September 17, 2026
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase III Clinical Trial of T-Bren for Injection (HER2 ADC) for Neoadjuvant Therapy in HER2-positive Breast Cancer
September 13, 2026
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase III Clinical Trial of Yizekang (Izalontamab Brengitecan, BL-B01D1/iza-bren) for Maintenance Therapy After Concurrent Chemoradiotherapy in Unresectable EGFR-Mutant Non-Small Cell Lung Cancer
September 9, 2026
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
September 6, 2026
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Special Report on the Deposit and Use of Raised Funds for the First Half of 2026
August 26, 2026
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Interim Analysis of Phase III Clinical Trial of Izalontamab Brengitecan (BL-B01D1/iza-bren) for Locally Advanced, Recurrent or Metastatic HR+HER2- Breast Cancer Achieving Primary Endpoint
August 25, 2026
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Interim Analysis of Phase III Clinical Trial of Izalontamab Brengitecan (BL-B01D1/iza-bren) for Locally Advanced or Metastatic Non‑Small‑Cell Lung Cancer Reaching Primary Endpoint
August 17, 2026
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Completing Administration of the First Subject in the Global Multicenter Phase‑III Clinical Trial of BL‑M14D1 (DLL3 ADC) for Injection Combined With Immunotherapy as First‑line Treatment for Extensive‑stage Small Cell Lung Cancer
August 6, 2026
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on the Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase III Clinical Trial of T-Bren (HER2 ADC) for Injection in Patients with HER2-Expressing Locally Advanced or Metastatic Biliary Tract Cancer Who Failed Platinum-Based Chemotherapy
July 26, 2026
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Completion of First Subject Enrollment in the Phase III Clinical Trial of BL-B01D1/iza-bren for the Treatment of Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-Based Chemotherapy
July 23, 2026
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Approval of the Marketing Application for BL-B01D1/iza-bren for Treatment of Esophageal Cancer
July 16, 2026
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Implementation Results of Share Repurchase
July 8, 2026
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Progress in Repurchasing Shares
July 2, 2026
Announcement on Resignation of Securities Affairs Representative
June 26, 2026
Announcement on Voluntary Disclosure of First Subject Enrollment in the Phase III Clinical Trial of Lenconelontuzumab/Yizekang (BL-B01D1/iza-bren) Combination Therapy for First-Line Extensive-Stage Small Cell Lung Cancer
June 25, 2026
Announcement on Voluntary Disclosure of the Approval for Market Launch of Izaberonramab (BL-B01D1/iza-bren)
June 22, 2026
Announcement on Voluntary Disclosure of Receiving Drug Clinical Trial Approval Notice for BL-M14D1 for Injection (DLL3 ADC) in Combination Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer
June 14, 2026
Announcement on Receipt of the Notice of Registration Acceptance from the National Association of Financial Market Institutional Investors
June 11, 2026
Announcement on Voluntary Disclosure of the IND Application for the Phase III Clinical Trial of BL-M14D1 (DLL3 ADC) in Combination with Immunotherapy for First-Line Extensive-Stage Small Cell Lung Cancer Receiving FDA Clearance
June 8, 2026
Announcement on Obtaining Letter of Commitment for Special Loans for Stock Repurchase from Financial Institution
June 5, 2026
Announcement on Voluntary Disclosure of the Completion of the First Subject Enrollment in the Phase III Clinical Trial of BL-M05D1 for Injection (ADC) for Previously First-Line Treated Claudin18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
June 4, 2026
Announcement on Shareholding of Top 10 Shareholders and Top 10 Shareholders without Sales Limit Concerning Shares Repurchase
June 3, 2026
Announcement on Initially Repurchasing the Company's Shares through Call Auction
June 2, 2026
Announcement on Resolutions of the 8th Meeting of the 5th Board of Directors
June 1, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 19, 2026
Announcement on Voluntary Disclosure of the Approval Notice for Drug Clinical Trial of SI-B036 Bispecific Antibody Injection for Treatment of Locally Advanced or Metastatic Solid Tumors
May 14, 2026
Announcement on Voluntary Disclosure of Completion of First Subject Enrollment in the Phase III Clinical Trial of T-Bren for Injection (HER2 ADC) for First-line HER2-positive Recurrent or Metastatic Breast Cancer
May 12, 2026
Announcement on Convening the 2025 Annual Collective Performance Briefing for Biological Products Industry on SSE STAR Market and the Q1 2026 Performance Briefing
May 8, 2026
Announcement on 2025 Annual Profit Distribution Plan
April 27, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
April 16, 2026
Announcement on Voluntary Disclosure of Obtaining Approval Notice for 2 Phase II/III Drug Clinical Trials of iza-bren (EGFR×HER3 Dual-antibody ADC) Combination Therapy in the Treatment of Advanced or Extensive-stage Solid Tumors
April 1, 2026
Notice on Convening the 2nd Extraordinary General Meeting in 2026
March 31, 2026
Announcement on Return of Raised Funds Temporarily Used to Supplement Current Capital
March 26, 2026
Announcement on Voluntary Disclosure of Receipt of Clinical Trial Approval Notice for BL-ARC002 in the Treatment of Advanced Solid Tumors
March 22, 2026
Announcement on Circulation of Restricted Shares Issued to Specific Objects
March 17, 2026
Announcement on Implementation Results of Share Repurchase
March 12, 2026
Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval Notification for BL-M11D1 (CD33-ADC) Injection for the Treatment of Relapsed or Refractory Myelodysplastic Syndromes
March 4, 2026
Announcement on Progress in Repurchasing Shares
March 3, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Announcement on Voluntary Disclosure of Interim Analysis of the Phase III Clinical Trial of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer Meeting the Primary Endpoint
February 23, 2026
Announcement on Resignation of the Secretary of Board of Directors and Assumption of the Secretary's Duties by Directors and Senior Management Members
February 13, 2026